Advertisement
Screener

ENANTA PHARMACEUTICALS, INC (ENTA) Increase (Decrease) in Unbilled Receivables

2.8 / 5 stars · 68/120 Roast Me

ENANTA PHARMACEUTICALS, INC Increase (Decrease) in Unbilled Receivables

ENANTA PHARMACEUTICALS, INC (ENTA) reported Increase (Decrease) in Unbilled Receivables of -$433.00 thousand for the 12-month period ending 2016-09-30, per its 10-K filed 2018-11-29.

Discontinued › Notes › Revenue Recognition and Deferred Revenue

us-gaap:IncreaseDecreaseInUnbilledReceivables · last filed 2018-11-29

  • ENANTA PHARMACEUTICALS, INC increase (decrease) in unbilled receivables for the quarter ending 2016-09-30 was $0.00.
  • ENANTA PHARMACEUTICALS, INC increase (decrease) in unbilled receivables for the quarter ending 2016-06-30 was $0.00.
  • ENANTA PHARMACEUTICALS, INC increase (decrease) in unbilled receivables for the quarter ending 2016-03-31 was -$1.01M.
  • ENANTA PHARMACEUTICALS, INC increase (decrease) in unbilled receivables for the quarter ending 2015-12-31 was $576.00K.
  • ENANTA PHARMACEUTICALS, INC increase (decrease) in unbilled receivables for fiscal 2016 was -$433.00K.
  • ENANTA PHARMACEUTICALS, INC increase (decrease) in unbilled receivables for fiscal 2015 was -$2.34M, a 217.67% decline from fiscal 2014.
  • ENANTA PHARMACEUTICALS, INC increase (decrease) in unbilled receivables for fiscal 2014 was $1.99M.
  • ENANTA PHARMACEUTICALS, INC increase (decrease) in unbilled receivables for fiscal 2013 was -$1.11M, a 158.58% decline from fiscal 2012.
Period endIncrease (Decrease) in Unbilled Receivables 3 monthIncrease (Decrease) in Unbilled Receivables 6 monthIncrease (Decrease) in Unbilled Receivables 9 monthIncrease (Decrease) in Unbilled Receivables 12 month
2016-09-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29
$0.00
derived: sum of 2 quarters · filed 2018-11-29
-$1.01M
derived: sum of 3 quarters · filed 2018-11-29
-$433.00K
10-K · filed 2018-11-29
2016-06-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09
-$1.01M
derived: sum of 2 quarters · filed 2017-08-09
-$433.00K
10-Q · filed 2017-08-09
-$1.38M
derived: sum of 4 quarters · filed 2017-12-11
2016-03-31-$1.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10
-$433.00K
10-Q · filed 2017-05-10
-$1.38M
derived: sum of 3 quarters · filed 2017-12-11
-$1.55M
derived: sum of 4 quarters · filed 2017-12-11
2015-12-31$576.00K
10-Q · filed 2017-02-09
-$367.00K
derived: sum of 2 quarters · filed 2017-12-11
-$541.00K
derived: sum of 3 quarters · filed 2017-12-11
-$873.00K
derived: sum of 4 quarters · filed 2017-12-11
2015-09-30-$943.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11
-$1.12M
derived: sum of 2 quarters · filed 2017-12-11
-$1.45M
derived: sum of 3 quarters · filed 2017-12-11
-$2.34M
10-K · filed 2017-12-11
2015-06-30-$174.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09
-$506.00K
derived: sum of 2 quarters · filed 2016-08-09
-$1.39M
10-Q · filed 2016-08-09
-$883.00K
derived: sum of 4 quarters · filed 2016-12-09
2015-03-31-$332.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10
-$1.22M
10-Q · filed 2016-05-10
-$709.00K
derived: sum of 3 quarters · filed 2016-12-09
-$54.00K
derived: sum of 4 quarters · filed 2016-12-09
2014-12-31-$888.00K
10-Q · filed 2016-02-09
-$377.00K
derived: sum of 2 quarters · filed 2016-12-09
$278.00K
derived: sum of 3 quarters · filed 2016-12-09
$953.00K
derived: sum of 4 quarters · filed 2016-12-09
2014-09-30$511.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09
$1.17M
derived: sum of 2 quarters · filed 2016-12-09
$1.84M
derived: sum of 3 quarters · filed 2016-12-09
$1.99M
10-K · filed 2016-12-09
2014-06-30$655.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-10
$1.33M
derived: sum of 2 quarters · filed 2015-08-10
$1.48M
10-Q · filed 2015-08-10
$1.28M
derived: sum of 4 quarters · filed 2015-12-11
2014-03-31$675.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-08
$820.00K
10-Q · filed 2015-05-08
$623.00K
derived: sum of 3 quarters · filed 2015-12-11
$836.00K
derived: sum of 4 quarters · filed 2015-12-11
2013-12-31$145.00K
10-Q · filed 2015-02-06
-$52.00K
derived: sum of 2 quarters · filed 2015-12-11
$161.00K
derived: sum of 3 quarters · filed 2015-12-11
$386.00K
derived: sum of 4 quarters · filed 2015-12-11
2013-09-30-$197.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11
$16.00K
derived: sum of 2 quarters · filed 2015-12-11
$241.00K
derived: sum of 3 quarters · filed 2015-12-11
-$1.11M
10-K · filed 2015-12-11
2013-06-30$213.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-12
$438.00K
derived: sum of 2 quarters · filed 2014-08-12
-$912.00K
10-Q · filed 2014-08-12
-$535.00K
derived: sum of 4 quarters · filed 2014-12-11
2013-03-31$225.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12
-$1.13M
10-Q · filed 2014-05-12
-$748.00K
derived: sum of 3 quarters · filed 2014-12-11
-$474.00K
derived: sum of 4 quarters · filed 2014-12-11
2012-12-31-$1.35M
10-Q · filed 2014-02-13
-$973.00K
derived: sum of 2 quarters · filed 2014-12-11
-$699.00K
derived: sum of 3 quarters · filed 2014-12-11
2012-09-30$377.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11
$651.00K
derived: sum of 2 quarters · filed 2014-12-11
$1.89M
10-K · filed 2014-12-11
2012-06-30$274.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12
$1.52M
10-Q · filed 2013-08-12
2012-03-31$1.24M
10-Q · filed 2013-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Emergent BioSolutions Inc. (EBS)United States$0.347B-2.43
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Rezolute, Inc. (RZLT)United States$0.382B-6.45
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63